Kamidono S, Arakawa S, Ishigami J, Sasai S, Kumamoto Y, Kawamura N, Ohkoshi M, Suzuki K, Naide Y, Ohkawa M
Department of Urology, Kobe University School of Medicine.
Hinyokika Kiyo. 1989 Mar;35(3):427-45.
The criteria for clinical evaluation of the efficacy of antimicrobial agents on prostatitis were proposed. Nomenclatural definition, specifications of patients and criteria were as follows. Acute prostatitis: Target infection is acute bacterial prostatitis with no underlying condition in urinary tract. The findings of swelling and tenderness of prostate by rectal examination are essential. The patients are between 16 and 69 years old. They have fever greater than 37 degrees C and pain on micturition. Microscopic examination reveals white blood cells (WBCs) in VB1 or VB2 before treatment greater than or equal to 10 cells/hpf. Viable bacteria in VB1 or VB2 before treatment are greater than or equal to 10(4) bacteria/ml. Period of treatment is for 7 days. To evaluate clinical efficacy, 3 days after administration, changes of symptoms (fever and pain on micturition) are recorded. Seven days after administration, changes of symptoms, microscopic examinations and number of bacteria are recorded. The overall clinical efficacy is graded as "excellent", "moderate" or "poor" by combining changes in the above 3 parameters. Chronic prostatitis: Target infection is chronic bacterial prostatitis with no underlying condition in urinary tract. The patients are between 16 and 69 years old. Microscopic examination reveals WBC in EPS or VB3 before treatment greater than or equal to 10 cells/hpf. Viable bacteria before treatment are greater than or equal to 10(3)/ml (GNR) or greater than or equal to 10(4)/ml (GPC). Treatment period is for 14 days. To evaluate clinical efficacy, after 14 days of administration, changes of symptoms, microscopic examinations and number of bacteria are recorded. The overall clinical efficacy is graded as "excellent", "moderate", or "poor" by combining the changes in the 2 parameters, microscopic examination and number of bacteria.
提出了抗菌药物治疗前列腺炎疗效的临床评价标准。命名定义、患者规格和标准如下。急性前列腺炎：目标感染为急性细菌性前列腺炎，尿路无基础疾病。直肠指检发现前列腺肿大和压痛是必要的。患者年龄在16至69岁之间。他们有体温高于37摄氏度和排尿疼痛。治疗前VB1或VB2的显微镜检查显示白细胞（WBC）大于或等于10个/高倍视野。治疗前VB1或VB2中的活菌数大于或等于10⁴个/毫升。治疗期为7天。为评估临床疗效，给药3天后，记录症状（发热和排尿疼痛）的变化。给药7天后，记录症状、显微镜检查和细菌数量的变化。综合上述3个参数的变化，将总体临床疗效分为“优”、“中”或“差”。慢性前列腺炎：目标感染为慢性细菌性前列腺炎，尿路无基础疾病。患者年龄在16至69岁之间。治疗前EPS或VB3的显微镜检查显示白细胞大于或等于10个/高倍视野。治疗前的活菌数大于或等于10³/毫升（革兰氏阴性菌）或大于或等于10⁴/毫升（革兰氏阳性菌）。治疗期为14天。为评估临床疗效，给药14天后，记录症状、显微镜检查和细菌数量的变化。综合显微镜检查和细菌数量这2个参数的变化，将总体临床疗效分为“优”、“中”或“差”。
